Pedro N Aguiar1, Ramon Andrade De Mello2,3,4, Peter Hall5, Hakaru Tadokoro1, Gilberto de Lima Lopes6. 1. Division of Medical Oncology, Federal University of São Paulo, São Paulo, SP, Brazil. 2. Department of Biomedical Sciences & Medicine, Division of Oncology, University of Algarve, Faro, Portugal. 3. Division of Medical Oncology, Clatterbridge Cancer Centre, Wirral & Liverpool, UK. 4. Catterbridge Cancer Centre, Clatterbridge Health Park, Clatterbridge Road, Birkenhead, Wirral, UK. 5. Department of Oncology, Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK. 6. Sylvester Comprehensive Cancer Center at the University of Miami, Miami, FL 33136, USA.
Abstract
AIM: The treatment of non-small-cell lung cancer has changed after the development of the immune checkpoint inhibitors. Although the most studied biomarker is PD-L1 expression, its clinical significance is still debatable. In this article, we show the updated survival analysis of all published data. METHODS: We searched in network and conference data sources for relevant clinical studies of immunotherapy for non-small-cell lung cancer that assessed the PD-L1 expression even as an exploratory analysis. The updated survival hazard ratios (HR) were included in the analysis. RESULTS: 14 studies with 2857 patients were included (2019 treated with immunotherapy). The response rate was as higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to better progression-free survival (HR: 0.69, 95% CI: 0.57-0.85) and better overall survival (HR: 0.77, 95% CI: 0.67-0.89). CONCLUSION: PD-L1 overexpression predicts activity as well as better survival for patients treated with immune checkpoint inhibitors.
AIM: The treatment of non-small-cell lung cancer has changed after the development of the immune checkpoint inhibitors. Although the most studied biomarker is PD-L1 expression, its clinical significance is still debatable. In this article, we show the updated survival analysis of all published data. METHODS: We searched in network and conference data sources for relevant clinical studies of immunotherapy for non-small-cell lung cancer that assessed the PD-L1 expression even as an exploratory analysis. The updated survival hazard ratios (HR) were included in the analysis. RESULTS: 14 studies with 2857 patients were included (2019 treated with immunotherapy). The response rate was as higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to better progression-free survival (HR: 0.69, 95% CI: 0.57-0.85) and better overall survival (HR: 0.77, 95% CI: 0.67-0.89). CONCLUSION:PD-L1 overexpression predicts activity as well as better survival for patients treated with immune checkpoint inhibitors.
Authors: Sarah A Joseph; Angelo Taglialatela; Giuseppe Leuzzi; Jen-Wei Huang; Raquel Cuella-Martin; Alberto Ciccia Journal: DNA Repair (Amst) Date: 2020-08-15
Authors: Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores Journal: Nat Rev Clin Oncol Date: 2017-10-10 Impact factor: 66.675
Authors: Audrey Player; Nissi Abraham; Kayla Burrell; Iria Ondo Bengone; Anthony Harris; Lisa Nunez; Telisa Willaims; Sharon Kwende; Wiley Walls Journal: Genes Cancer Date: 2017-07
Authors: Musa AlHarbi; Nahla Ali Mobark; Latifa AlMubarak; Rasha Aljelaify; Mariam AlSaeed; Amal Almutairi; Fatmah Alqubaishi; M Emarat Hussain; Ali Abdullah O Balbaid; Amal Said Marie; Lamia AlSubaie; Saeed AlShieban; Nada alTassan; Shakti H Ramkissoon; Malak Abedalthagafi Journal: Oncologist Date: 2018-08-13
Authors: Sandra van Wilpe; Sofie H Tolmeijer; Rutger H T Koornstra; I Jolanda M de Vries; Winald R Gerritsen; Marjolijn Ligtenberg; Niven Mehra Journal: Cancers (Basel) Date: 2021-05-07 Impact factor: 6.639